Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
Susan BullmanBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAChandra Sekhar PedamalluBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAEwa SicińskaDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USAThomas E. ClancyBrigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAXiaoyang ZhangBroad Institute of MIT and Harvard, Cambridge, MA 02142, USADiana CaiBroad Institute of MIT and Harvard, Cambridge, MA 02142, USADonna NeubergDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USAKatherine HuangBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAFatima GuevaraDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USATimothy NelsonDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USAOtari ChipashviliDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USATimothy HaganDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USAMark WalkerBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAAruna RamachandranBroad Institute of MIT and Harvard, Cambridge, MA 02142, USABegoña DiosdadoBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAGarazi SernaVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainNuria MuletVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainStefania LandolfiVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainSantiago Ramón y CajalVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainRoberta FasaniVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainAndrew J. AguirreBrigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAKimmie NgDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USAElena ÉlezVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainShuji OginoBrigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAJosep TaberneroVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainCharles S. FuchsYale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USAWilliam C. HahnBrigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAPaolo NucíforoVall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, CIBERONC, Universitat Autònoma de Barcelona, SpainMatthew MeyersonBrigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2017en
ABI
Аннотация
Bacteria go the distance in cancer The bacterial species Fusobacterium nucleatum is associated with a subset of human colorectal cancers, but its role in tumorigenesis is unclear. Studying patient samples, Bullman et al. found that F. nucleatum and certain co-occurring bacteria were present not only in primary tumors but also in distant metastases. Preliminary evidence suggests that the bacterium is localized primarily within the metastatic cancer cells rather than in the stroma. Antibiotic treatment of mice carrying xenografts of F. nucleatum –positive human colorectal cancer slowed tumor growth, consistent with a causal role for the bacterium in tumorigenesis. Science , this issue p. 1443
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0